Abstract
Ristocetin-induced platelet aggregation (RIPA) is used as an in vitro test to determine the presence and integrity of the platelet glycoprotein (GP) Ibα-V-IX complex and von Willebrand factor (VWF) interaction and is usually performed using platelet-rich plasma (PRP). Impairment in the response of VWF/GPIbα-V-IX is measured with reference to several established concentrations of ristocetin and may indicate defects in VWF or in GPIbα-V-IX function. RIPA-based mixing studies comprise an additional approach to testing this interaction to help define whether defects identified by RIPA lie in VWF or in GPIbα-V-IX. For example, the correction of an abnormal RIPA trace after mixing PRP with normal plasma and rechallenging with ristocetin at 1.0 mg/mL suggests VWF function/quantity defect. RIPA mixing studies at lower doses of ristocetin (0.5 mg/mL) are recommended for discrimination of von Willebrand disease type 2B (VWD2B) from the rarer platelet-type (PT) VWD and for the phenotypic laboratory diagnosis of VWD2B. The demonstration of a plasma factor capable of inducing platelet aggregation at such low doses of ristocetin represents the hallmark for the phenotypic laboratory diagnosis of VWD2B. Moreover, since both VWD2B and PT-VWD may present with thrombocytopenia, RIPA-based mixing studies are also useful in thrombocytopenic patients in whom RIPA testing is difficult to assess.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Favaloro EJ, Lippi G, Franchini M (2010) Contemporary platelet function testing. Clin Chem Lab Med 48:579–598
Howard MA, Firkin BG (1971) Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 26:362–369
Howard MA, Sawers RJ, Firkin BG (1973) Ristocetin: a means of differentiating von Willebrand’s disease into two groups. Blood 41:687–690
Favaloro EJ (2008) Phenotypic identification of platelet type-von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of non-identical twins? Or two-sides of a multi-denominational or multi-faceted primary haemostasis coin? Semin Thromb Hemost 34:113–127
Favaloro EJ, Patterson D, Denholm A, Mead S, Gilbert A, Collins A, Estell J, George PM, Smith MP (2007) Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease from type 2B VWD using a simplified ristocetin-induced-platelet-agglutination (RIPA) mixing assay and confirmed by genetic analysis. Br J Haematol 139:623–626
Othman M, Kaur H, Favaloro EJ, Lillicrap D, Di Paola J, Harrison P, Gresele P, for the Subcommittees on von Willebrand Disease and Platelet Physiology (2016) Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. J Thromb Haemost 14:411–414
Bonar R, Favaloro EJ, Adcock D (2010) Quality in coagulation and haemostasis testing. Biochem Med 20:184–199
Favaloro EJ (2009) Internal quality control and external quality Assurance of Platelet Function Tests. Semin Thromb Hemost 35:139–149
Hayward CPM, Eikelboom J (2007) Platelet function testing: quality assurance. Semin Thromb Hemost 33:273–282
Bonduel M, Frontroth JP, Hepner M, Sciuccati G, Feliú-Torres A (2007) Platelet aggregation and adenosine triphosphate release values in children and adults. Thromb Haemost 5:1782–1783
Scharf RE (2012) Drugs that affect platelet function. Semin Thromb Hemost 38:865–883
McEwen BJ (2014) The influence of diet and nutrients on platelet function. Semin Thromb Hemost 40:214–226
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Frontroth, J.P., Favaloro, E.J. (2017). Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_35
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_35
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols